Emerging Therapy Retatrutide Retatrutide is a new emerging (LY-3437943) is a triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors currently under trial conducted by Eli Lilly and Company Mechanism of Action GIP agonism enhances insulin release, suppresses appetite, inhibits fat accumulation GLP-1 agonism enhances insulin release, suppresses glucagon, slows gastric emptying Glucagon receptor agonism boosts energy expenditure, supports glycemic control Collectively, it addresses glucose homeostasis, appetite regulation, energy metabolism, and weight loss Competitive Edge over Existing Therapies Superior efficacy: Around 24% weight loss surpasses GLP-1-only treatments (e.g., semaglutide, tirzepatide)
Comparing Semaglutide and Tirzepatide FeatureSemaglutideTirzepatideMechanismGLP-1 receptor agonistDual GLP-1 and GIP agonistWeight LossUp to 15% body weight lossUp to 20% body weight lossDosingOnce weeklyOnce weeklyGlycemic ControlYesYesFDA ApprovalApproved for weight lossRecently approved for weight loss What to Expect During Your Treatment At Better Me Med Spa & Wellness Center, we prioritize your health and satisfaction as you embark on your weight loss journey with either semaglutide or tirzepatide: Consultation: Your experience begins with a detailed consultation, where our healthcare professionals will assess your weight loss goals, medical history, and lifestyle to determine the best treatment for you
Teaching patients to spot early signs of serious side effects is crucial
This is part of a broader strategy to maintain trust and improve patient outcomes
(CMS) Formularies and plan differences: Even when Medicare can cover, which Part D plan you have makes a big difference
